ASCO updates guidelines for NSCLC therapy

The American Society of Clinical Oncology released updated guidelines for treating advanced non-small cell lung cancer (NSCLC) to incorporate advances in cancer immunotherapy.

Key recommendations for first-line therapy include the use of PD-1 mAb Keytruda pembrolizumab in patients without EGFR mutations or ALK or ROS1 rearrangements. Within that population, ASCO recommends the use of Keytruda as monotherapy in patients with high PD-L1 expression. It does not recommend other checkpoint inhibitors or combinations of checkpoint inhibitors with or without chemotherapy. The organization does not recommend Keytruda for patients with low PD-L1 expression. Instead, it recommends chemotherapy only...